#novel approaches in cancer study

[crimsonpublisherscancerstudy]

Recent Advances in the Therapeutic Approaches of Glioblastoma Multiforme_Crimson Publishers

Abstract

Glioblastoma Multiforme (GBM, WHO grade IV) is one of the most aggressive, invasive, and lethal intracranial neoplasms, with a low post-diagnosis survival rate. Standard-of-care treatment regimens involving maximal surgical resection, radiotherapy, and genetic anti-tumor compounds like Temozolomide have only been marginally effective in improving overall survival and quality of life. Cell fusion, autophagy, and other complex biological processes affecting GBM pathophysiology are being studied to improve GBM treatment. This paper therefore focuses on oncolytic virus therapy combined with surgical resection, photodynamic therapy, and novel gene therapy, demonstrating how GBM treatment for patients could result in immediate and authentic tumor cytotoxicity and removal, rather than treatment of recurrent GBM. Standard therapy for GBM, including surgery, radiotherapy, and chemotherapy, is called the Stupp regime with the inclusion of Temozolomide (TMZ). It is extremely difficult to design new and effective therapeutic approaches because of the numerous complex biological pathways involved in GBM pathogenesis. Even Stupp regime clinical outcomes have only shown modest benefits with less than 10% of overall 5-year survivorship. A major contributing factor in GBM development is also its interaction with the patient’s host immune system.

Read more about this article:

For more articles in Novel Approaches in Cancer Study

[darkmaga-retard]

A group of eminent medical experts and leading scientific researchers has announced a major breakthrough after a groundbreaking study discovered an “off switch” for Covid mRNA shots.

The historic discovery, which offers hope to the billions of people around the world who have been injected with the “vaccines,” was revealed in a recent preprint study.

Contrary to initial claims that the “vaccine” stays in the arm, it spreads throughout the body.

The spread of the mRNA from the shots is prompting serious safety concerns from leading experts.

The spike protein triggered by the mRNA from the shots has been linked to multiple deadly diseases and sudden death.

The mRNA shots are believed to be responsible for surging cases of turbo cancers, heart failure, strokes, blood clots, and damaged immune systems.

However, the groundbreaking new discovery gives hope for approximately 5.5 billion people to “inactivate” what they put into their bodies.

The new study was led by renowned American cardiologist Dr. Peter McCullough.

McCullough and his team presented a novel approach using small interfering messenger RNA (siRNA) and ribonuclease targeting chimeras (RIBOTACs) to bind and deactivate the mRNA from these vaccines.

[thefloatingpickle]

All Shook Up

A bored, lonely librarian gets a break from the mundane when a night out leads to a meeting with Tom Bennett. Tom!FemOC Older woman (not by much)

Please excuse errors I have no one checking this for me

Triggers for a bit of a tough spot towards the end

_____________________

London was nothing like what Adaline Harper imagined it would be. Back home in Chicago she had dreamed it into a mythical world of fairytales and gentlemen. In reality she had seen very little in the way of magical thinking and even less of a gentleman since coming over at twenty two to finish her masters in Library Sciences. Don’t get it wrong, she was glad she had come, spending the rest of her life toiling away on the north side of the city with her alcoholic father and useless brother was her worst nightmare. Losing her mother so young from cancer after watching her waste away at the service of her cold hearted, often cruel father only fueled her need to escape. Originally she had only planned to go as far as maybe the east coast, but when she was presented the opportunity to study abroad by her favorite English professor she jumped at the chance. 

 Unfortunately for Adaline she had not been swept off her feet by a strapping young brit like she had imagined. Much to the contrary she went on several dates with mostly what would be considered posh type men she met attending classes, and all of them were only interested in the rumors that American girls were quick to the sheets. So she had quit trying and dedicated herself to her studies. When she finished she was quickly awarded a position at Central Library in Manchester. 

 She liked it well enough, the head librarian was a stout cold woman, but she often brought in food for the girls who worked the stacks and had even brought Adaline a gift of a beautiful sterling silver necklace with a small pendant in the shape of a book for starting in her new position. She worked the main desk in non fiction. It was mostly long boring days, academics and curious minds coming to find this book or that, but on slow days she could go into the shelves and find herself something interesting to keep her mind busy, history had always been a favorite subject.

 It was in the middle of one of these slow days that the slightly younger girls who worked reshelving the checked in books in her section approached her for what may be the hundredth time about going out with them for a drink after work. “You can’t spend every night curled up in your flat reading romance novels, can ya Addie?” Tilly, the louder of the two girls with her beautiful blonde hair and lean features announced too loud for the surroundings. “It was one romance novel Tilly, ONE!” Addie spit back in a harsh whisper. “One or ten it’s still a sad sight. You being only what Twenty-Five and all? Come out with us, you’d have a blast. None of those uptight wankers you’ve talked about dating at Uni, our mates are fun!” Becky, the sweeter  of the two, pleaded with you. Her brown hair stopping just above her shoulders showed off her sharp jawline, which seemed unusual given the softness of the rest of her features. “I have letters to write. My aunt has been bombarding me with posts for the last two months and I haven’t gotten back to her or my nieces.” 

 They rolled their eyes in unison, “You could write during work you know. We all do. Besides it is my BIRTHDAY” “I like to write in the privacy of my home thank you.” “Ugghhh,” “Quiet!” The head librarian had heard the noise from the main lobby and made her way in to announce that you were bothering the small smattering of patronage the building had pulled in on the clear spring day. “Sorry Ma’am.” Addie whispered. “Get back to your shelving girls, I appreciate the invite but going drinking with a bunch of twenty year olds isn’t my idea of a good time.” 

 With a chuff and a turn they were back to work and you were grateful for the silence until he walked in. “Addie girl, you look dashing as ever.” “Hello Greg, how are you today?” You couldn’t stand Greg, he had seemed nice at first but after the fourth time he asked you to dinner you started running out of good excuses. Not that he wasn’t handsome, but his parents were on the board for the library and he strutted around the place like it made him a prince. “You know they’ve just opened a lovely new cafe down off of Pike street, a beautiful view of the Medlock from the outside seating.” Her stomach turned as she felt the question coming, “Oh yea? Sounds lovely.” “It is, and I was just thinking how lovely you would look sitting there.” “That’s kind of you to say.” “Isn’t it? How about tonight?” She wracked her brain for an excuse, any excuse, just then she caught the sight of Tilly watching her interaction with a satisfied smirk. “I can’t, you see I already have plans.” He lifted a brow in surprise, “Plans? You, to do what?” “Well you see it’s Tilly’s birthday and I’ve promised to get a drink with the girls down at a pub later.” He didn’t believe you for a second. “You… are going to a pub with Tilly and Becky?” Like a saving angel Becky popped up from behind you. “Oh yes, she is. We had to practically beg. But you know even Adaline isn’t monster enough to miss out on Tilly’s celebrations.” I let out a sigh of relief as he walked away seeming flabbergasted. “Thank you Becky, I owe you one.” “Don’t be thanking her too fast now Addie, you’re coming to the pub tonight or I’m going to run right behind the good lad and tell him you’ve played him a fool.” Tilly said head peeking out from the stacks with a grin on her face.

_____________________

“I cannot believe I roped myself into this”, Addie thought as she made her way down the cobblestone path, her mary janes clicking loudly off the road at every step. She had agreed to meet the girls at McDuff’s, a known hang out for the sort of kids Tilly and Becky liked to spend their time around. Petty criminals who were just as likely to walk out on a tab as they were to start a street fight just in the name of a couple minutes entertainment. 

 She’d gone home from Central and put on one of the few dresses she had that were more suited for a night out than a day at work, the deep green dress went perfectly with her pale skin, and auburn hair. She had had to dig through half of her vanity drawers to find the one shade of lipstick she had that wasn’t just a pale nude, but the red went well with the dress and for once she felt a bit pretty. 

She heard the place before she saw it, rumpus laughter and loud music pouring out the door as she rounded the corner.``You actually came!” A shout rose out over the noise. “Hello, Tilly. Happy birthday.” Was all she got out as she led you into the small but jovial building. “Everyone, THIS is Adaline! She came!!” Adaline almost felt bad, she didn't realize it would make such a difference to Tilly whether she had come or not. “You must meet everyone.” The young woman exclaimed as she led her over to a section of standing tables swarming with people. “Obviously you know Becky, then this is Adam, Luke, Nathaniel, Jackie, Devlen, and Peter.” You couldn’t help but notice how intensely male company outweighed the female. “Hello, nice to meet everyone.” “And what about me then?” A voice came from behind, it was pleasant with a sort of smugness that suggested confidence. “Oh yes we can’t forget you can we,” Tilly said, turning her to meet the newcomer, “this is Tom.” He had a wide smile on his face that was friendly in a cocky way, but damn if he wasn’t handsome. “Hello, luv.” He reached out his hand to her expectantly. “Hi” Addie took his hand and was surprised by how tightly he gripped the shake. “Always a pleasure  meet’in a lass lovely as yourself.” She couldn’t help but roll her eyes. “I’m sure it is.” Her quick remark gained her another wide grin. “Drinks all around then?” He put the question to the group but never broke eye contact. “Yes please!” Tilly said in reply, as he turned to leave she leaned in and whispered in Addie’s ear, “Careful with that one, he fancies himself a heartbreaker but has about as much game as a sailor in the desert.” The girls laughed at the joke and shortly after Addie found herself with a drink in hand enjoying the night more than she had expected. 

 The music was almost too loud for conversation but the girls' friends were funny, and light hearted. Addie felt almost guilty for avoiding them for so long, but often also felt the distinct gap in age as one would make a comment about being nineteen or twenty and at that she would take another large gulp of her drink, which seemed to always be magically replenished when she would finish. Everything was going well, except that every so often she would feel a set of eyes on her and when she turned to see who it was it was always Tom. He was quieter than she had expected, choosing more to watch and listen than to speak up and join the cycle of storytelling, but his presence loomed over her in a way that made her unsure of herself. She often found herself checking her compact to make sure her lipstick was in place, or pulling at the hem of her dress to check it was sitting right, and every time she did she would look over to find another too confident smirk across his face. After a couple hours she decided she needed a smoke and stepped outside, though as soon as she had her cigarette between her lips she realized she couldn’t find her lighter in her small handbag. “Dammit.” A quiet laugh came from behind her, “Trade you a smoke for a light?” She knew who it was before turning her head. “Alright Tom.” She agreed, handing him her smokes. He took one and placed it between his long thin lips, then held up his lighter in front of her smoke. “Pretty ladies shouldn’t be lighin’ their own sticks.” She couldn’t help the smile, or the blush that came over her cheeks, “Thank you.” “Thank you.” He replied and then they stood mostly in silence smoking. “How do you know Tilly then?” The question had almost startled her out of her own wandering train of thought, “Oh, uh, we work together at the library.” He smiled, “A jumpy bit you are eh? You can’t be a cart girl though can you?” She felt the flush of embarrassment come over her. “Why is that?” “Well, not for nothing but you look a touch grown to be reshelving books.” “So I look too old then? Well no I’m not a cart girl, I’m a librarian. I work the non fiction desk.” There was a bite to her tone that he seemed to catch quickly. “Now hold on lovely, wasn’t calling you old. I said grown. You’re clearly not some twenty year old girly.” “And what about you Tom? A ripe old, what eighteen?” He grimaced at that. “I’m twenty years old, I’ll have you know, a grown man. And I promise that means in every way that counts.” He gave another confident smirk. “Well twenty is still awfully young for me, being twenty five and all.” “Five years aint much unless you make something.” At that he leaned closer, tossing the burned end of his smoke to the side. “Bet I could make you feel twenty again.” He pressed himself closer to her, coming around to face her directly and Addie was suddenly very aware of not only the brick wall behind them but the years past since a man had been this close. “I’m sure it would be a valiant effort Tom but unfortunately I’m not interested.” She couldn’t meet his eyes because she knew he would find the lie in them. “Are you not, weren’t you in there fixing your lips, and touching up your skirts every time you looked at me.” “You were the one starring Tom, it made me…” Her voice trailed off, not waiting to admit he had any affect. “Nervous?” He finished for her a glint of pride in his eye that now drove her to annoyance. “I’d like to go back in now please.” She was stern in her tone. His smile dropped and he stepped out of the way. “Alright love, no harm intended.” He stayed behind as she walked back in and she didn’t see him again for the next hour she stayed. Finally ready to go home she went looking for Tilly to say good night, when she found her she was outside in the alley smoking, with Tom leaned against her side. Addie didn’t know why the sight bugged her but it did. So instead of approaching to say goodbye she simply yelled over her shoulder as she walked away. “Happy birthday Tilly, thanks for the invite.”  “Bye Addie!” She heard her yell, a small giggle escaping her. 

Adaline didn’t hear the footsteps behind her until they were almost on top of her. “Well Ello’ there pretty lady.” The first man said, “Too late to be walking home alone isn’t it.” The second followed. Addie was panicked, she was too far from the bar to turn around, but still several blocks from home. “I’m actually just walking to meet a friend. They don’t live too far off from here.” She prayed they would care, they didn’t. The first one reached forward and grabbed her wrist as the other came around behind her. “I don’t think you know anyone from round these parts miss.” One said. “Please just let me go home.” She had never been more afraid in her life. “Oh we will, right when we’re done with you.” Bile rose in Addie’s throat as she realized she was trapped. “Oi, you there. Watcha on about then?” The shout came from about a block behind, and sounded familiar. “None of your business lad so piss off.” “Is that you Erik? And Shawn then is it? I know you too, work over at the butchers driving the truck. Doubt Mr. Ebbes would be thrilled to hear what you’re getting up to here?” Tom came into sight and was as much of a relief as Addie had ever felt. “We weren’t up to nothin Tom, no need to be gossiping about. Just wanted to see the lady safely home is all.” “Well I’ll take her off your hands boys, no worries there.” The two men disappeared down a side road and Addie turned to  face Tom again. 

 “Oh god, thank you.” She couldn’t help the red hot tears as they slipped down her face. “Hey there, we’ll have none of that.” He said reaching up to wipe them away with a gentle touch from the back of his knuckle. “Nothing bad happened, you’re alright.” “Because of you.” She said, voice shaky. “What were you doing anyway?” “Walking home, I live just round this corner here, didn’t see much point in sticking around…” He looked at her, a small soft smile on his lips, “after you left that is.” Addie stood straightening her dress and hair, “And what about Tilly?” “What about her?” His brows rose in realization, “You mean in the alley? Us being close? Wasn’t anything meant by it, I’ve known her since we were kids.” They had started walking in the direction of home as he spoke. “Tilly may be my oldest mate, we’re just familiar like that. Wasn’t trying to make a move on her.” “Oh.” Addie’s voice was soft in reply, then she caught herself, “Not that it matters if you were, she’s more appropriate for you anyway.” “Appropriate?!” He nearly cackled, “What are you my babysitter now? Five years isn’t a leap you know, if I was the girl, and you were me no one would so much as blink. You’ve got yourself in your head over nothing.” “You're the same age as my baby brother Tom.” “Yea, well that is unfortunate but doesn’t make a lick of difference to my point.” The two of them walked in comfortable quiet the next few blocks until she realized they had come up on her place. “This is me.” “Right then.” He smiled at her again, “You work tomorrow?” “No, it’s Saturday, I have things to get done around though.” “Alright, well when do you work next?” “Why?” “Thought I may stop in and get a library card is all.” “Tom it wouldn’t be…” “Appropriate?” He cut her off. “Yes.” Before she could say anything else he leaned forward and pressed his lips to hers. He was sure of himself, working open her lips and slipping in his tongue before she could catch herself. He tasted like cigarettes and beer, but god did he feel good. Slim body pressing against her as he wrapped his arms around her waist, her hands went to his chest before she could stop herself. He pressed the kiss deeper, pulling her tongue to his mouth as he backed them to the doorway, one hand coming to rest on her neck. Then her senses came back to her and she pulled away. “Mhmm.” Was all he said as she pushed against him where her hands rested. “Thank you for walking me home Tom… I… I need to get to bed.” He backed up with no resistance. “Alright.” He seemed unaffected by her abruptly ending their contact as he turned to go. “See you soon Adaline.” He said in a sing-song tone as he walked down the road, whistling to himself as he went.

[jcmarchi]

Innovative Chemotherapy Approach Shows Promise Against Lung Cancer - Technology Org

New Post has been published on https://thedigitalinsider.com/innovative-chemotherapy-approach-shows-promise-against-lung-cancer-technology-org/

Innovative Chemotherapy Approach Shows Promise Against Lung Cancer - Technology Org

Lung cancer is not the most common form of cancer, but it is by far the deadliest.

Kytai T. Nguyen, the Alfred R. and Janet H. Potvin Distinguished Professor in Bioengineering at UTA. Image credit: UTA

Despite treatments such as surgery, radiation therapy and chemotherapy, only about a quarter of all people with the disease will live more than five years after diagnosis, and lung cancer kills more than 1.8 million people worldwide each year, according to the World Health Organization.

To improve the odds for patients with lung cancer, researchers from The University of Texas at Arlington and UT Southwestern Medical Center have pioneered a novel approach to deliver cancer-killing drugs directly into cancer cells.

“Our method uses the patient’s own cellular material as a trojan horse to transport a targeted drug payload directly to the lung cancer cells,” said Kytai T. Nguyen, lead author of a new study on the technique in the peer-reviewed Bioactive Materials and the Alfred R. and Janet H. Potvin Distinguished Professor in Bioengineering at UTA. “The process involves isolating T-cells (a type of immune cell) from the cancer patient and modifying them to express a specific receptor that targets the cancer cells.”

The crucial step in this new technique involves isolating the cell membrane from these modified T-cells, loading the membranes with chemotherapy medications, and then coating them onto tiny drug-delivery granules. These nanoparticles are roughly 1/100 the size of a strand of hair.

Jon Weidanz, associate vice president for research and innovation and professor of kinesiology and bioengineering. Image credit: UTA

When these membrane-coated nanoparticles are injected back into the patient, the cell membrane acts as a guide, directing the nanoparticles to the tumor cells with precision. This approach is designed to deceive the patient’s immune system, as the coated nanoparticles mimic the properties of immune cells, avoiding detection and clearance by the body.

“The key advantage of this method lies in its highly targeted nature, which allows it to overcome the limitations of conventional chemotherapy that often lead to detrimental side effects and reduced quality of life for patients,” said co-author Jon Weidanz, associate vice president for research and innovation and a researcher in kinesiology and bioengineering.

“By delivering chemotherapy directly to the tumor cells, the system aims to minimize collateral damage to healthy tissues,” continued Weidanz, who also is a member of UTA’s Multi-Interprofessional Center for Health Informatics.

In the study, researchers loaded the nanoparticles with the anti-cancer drug Cisplatin. The membrane-coated nanoparticles accumulated in parts of the body with the tumors rather than in other parts of the body. As a result, this targeted delivery system reduced the size of the tumors in the control group, demonstrating its efficacy.

“This personalized approach could pave the way for a new era of medicine tailored to each patient’s unique characteristics and the specific nature of their tumor,” Nguyen said. “The potential for reduced side effects and improved effectiveness makes our technique a noteworthy advancement in the field of cancer treatment.”

Source: University of Texas at Arlington

You can offer your link to a page which is relevant to the topic of this post.

[medchemexpressinhibitor-blog]

Exploring the Potential of a Glutamine Transporter Inhibitor

Introduction

Cancer cells exhibit distinct metabolic characteristics, and targeting specific metabolic pathways has become an area of intense research in cancer therapeutics. JPH203, a glutamine transporter inhibitor, has emerged as a promising drug candidate for disrupting the metabolic processes crucial to cancer cell survival and proliferation. This article aims to explore factual evidence regarding the efficacy and potential applications of JPH203.

Understanding JPH203

JPH203 is a selective inhibitor of the glutamine transporter ASCT2 (alanine, serine, cysteine-preferring transporter 2). ASCT2 plays a critical role in transporting glutamine, an amino acid essential for cancer cell growth and survival[¹^]. By targeting ASCT2, JPH203 aims to disrupt glutamine uptake and subsequently alter cancer cell metabolism.

The Mechanism of Action

Inhibition of Glutamine Uptake: JPH203 binds to ASCT2, preventing the transport of extracellular glutamine into cancer cells. This disruption hampers the availability of glutamine, an essential nutrient for cancer cell metabolism, thereby impairing their growth and survival[²^].

Factual Evidence Supporting JPH203

Preclinical Studies: Initial preclinical studies have demonstrated the efficacy of JPH203 in inhibiting cancer cell growth across various types of cancers, including lung, breast, pancreatic, and colorectal cancers[³^][⁴^]. These studies have shown that JPH203 treatment led to reduced glutamine uptake, impaired cell proliferation, and increased cell death.

Combination Therapy: JPH203 has been investigated in combination with other anticancer agents, such as chemotherapeutic drugs and targeted therapies. Preclinical studies have suggested synergistic effects when JPH203 is used in combination with other treatments, leading to enhanced anticancer activity[⁵^][⁶^]. These findings highlight the potential of JPH203 as an adjunct therapy to improve treatment outcomes.

Metabolic Reprogramming: Glutamine is a crucial nutrient for cancer cells, serving as a building block for macromolecules and as a source of energy. By inhibiting glutamine uptake, JPH203 disrupts cancer cell metabolism. This metabolic reprogramming can render cancer cells more susceptible to other therapies and potentially overcome drug resistance[⁷^].

Clinical Development

JPH203 is currently undergoing clinical trials to evaluate its safety, tolerability, and efficacy in patients with advanced solid tumors. These studies aim to determine the optimal dosage, treatment duration, and potential side effects to further establish the therapeutic potential of JPH203 in clinical settings[⁸^].

Conclusion

JPH203, a selective inhibitor of the glutamine transporter ASCT2, shows promise as a targeted approach to disrupt cancer cell metabolism. Preclinical studies have demonstrated its ability to inhibit glutamine uptake, impair cancer cell growth, and enhance cell death. The ongoing clinical trials will provide valuable insights into the safety and efficacy of JPH203 in human patients and its potential as part of combination therapies.

While JPH203 holds significant potential as a novel anticancer agent, further research is needed to fully understand its mechanisms of action, optimize treatment strategies, and identify the patient populations that may benefit most from its use. The development of JPH203 represents an exciting advancement in the quest for more effective and targeted cancer therapeutics.please visit MedChemExpress

(Note: This article is for informational purposes only and should not replace professional medical advice. Always consult your healthcare provider for personalized treatment recommendations.)

[justsomeoneintoomanyfandoms]

HIIII I see that u hv a match up goin on and Id like to try! Would u mind doing one for me with Obey Me?

Pronouns : She/they

Sexuality: Im not sure exactly??... still discovering but I know that I like both sexes

Infp 4w5 / Cancer sun Taurus moon n Scorpio rising (I saw some doing not just the sun sign so i think it would be fun if i include all 3 lol)

Appearance: Im South East Asian. Around 5'2. I hv shoulder length black hair, black eyes and olive toned skin. My hairstyle is akin to the jellyfish hair. I rarely wear makeup and would just hv my bare face out due to its sensitivity to breakouts. And my clothing, its mostly modest/covering for academic places or just comfy and quick with any cool baggy tees i hv. Its my current closet, since i dont hv much occasions to go grand and i just wanna blend in with everyone around me lookin like an npc. But id love to wear more self expressing stuff in the future, to my desire. More accessories, colorful makeups and fashions like dark couquette/gyaru or so!

Personality: My personality, id say its two sided. I guess hv an open mind and easy going (to some degree ofc). A dream chaser and a listener. Sometimes (just sometimes), i can get my mind through a problem and stay grounded. Im also empathic? I like consoling with people and I appreciate the smallest details. I feel for people's struggle and I hold hopes in them. However, i can get moody, its so unexpected and intense that even im scared of it. I can be very quiet then, and dissociative. Id just want to be alone by that time to figure out my situation. Ive been said to appear gloomy or hard to approach too :cry: If im pissed, im venomous. And im actually an anxious person, of all sorts of things. Self deprecating too, i almost forgot abt that. But if i feel suitable, i get funky and enjoy myself hehe.

Likes/Dislikes : I like visual novels, rhythm games and those with good storytelling; a variety of music genres that focus on melody, instrument, composing; local asian food; sleeping with plushies; arts n crafts; esoteric things; philosophy study; my friends; solitude and continuation; aesthetic or hidden values and uhhh nice, mannered intriguing people.

I dont like smelly people doe. People who are narrow minded icks me oops. Pls dont tryna barge in on me when im busy unless it helps. I hate the sun... And not getting myself tented after a long day. I dislike my parents as well, yikes. Worst of all, being opressed.

Hobbies : doll, bracelet making; drawing, online shopping, rhythm game arcade, reading philosophy works, uhh getting invested in random medias...

Anyways, thats my submission! If u do reply, tysm for the matchup!!!

Hi Anon! Thank you for the request! I hope you like your matchup!

In Obey Me, I match you with...

Asmo is the best person to hype you up about wearing more self-expressing things. He’s great at putting outfits together and will give you honest and genuine feedback.

Doesn’t mind your personality changes. He knows what mood swings are like so he’s very understanding.

Please go online shopping with him! But set a budget because you’re both liable to get caught up in the energy and spend too much. But online shopping with Asmo would be so much fun.

Not great at giving you alone time but if you say you need some space, he’ll respect your wishes. While you’re enjoying your alone time, he’ll do a spa day or hang out with some of his friends.

Asmo loves your plushies. He thinks they’re really cute and, if you’re okay with it, would love to borrow some of them to sleep with as well. He’ll take good care of them and swaps them out occasionally so you’ve got a constantly rotating roster of plushies in your room.

[ariel-seagull-wings]

JANINE AND EGON'S WEDDING QUESTIONS (MOVIE, NOVELIZATION AND COMICS VERSE)

@spengnitzed @bixiebeet @professorlehnsherr-almashy @angelixgutz

Imagine what music they'd have? What food? Would it be outside? What kind of theme, if any, would they have?

Jazz and jewish folk music. The ceremony would be outside in the garden, while the dinner reception, with Ashkenazi jewish food from Poland, Russia and Ukraine and the dancing party would be inside the house of their friend, Ray. The theme would be woodlands and mycology. 

Who would they invite? 

Ray (who is Egon's best man and provider of the house where the wedding is celebrated), Winston, Peter, Dana, Egon's mother, brother, sister-in-law and baby nephew, Janine's parents, sister, grandmother and maternal uncles and cousins. 

What season is it? Day or night? What colors do people wear?

Autumn, evening till night, starting at 15:00 pm. While the decoration is green and brown, the guests are left free to choose the colors of their clothes.

Is it traditional or do they do something wild?

The ceremony follows traditional jewish marriage rituals, along with including a justice of peace to assist the civil legalization and documentation of the wedding. 

Did they write their own vows? Who is the priest/priestess/minister marrying you? Or is it a family member or other platonic F/O?

They do write their own vows, taking some inspiration from literature. Janine's family rabbi and a paid justice of peace marries her and Egon. 

Are they wearing suits? Dresses? Something else entirely?

Janine wears a tea-length dress with a lace top and puffy skirt.

Egon wears a black suit and bowtie. 

What is their cake like if they have one?

Is a cake decorated with candy mushrooms and sugar leafs, topped with two snails representing the couple. 

Do they throw the bouquet for someone to catch or do they pass out one flower to everyone so they let everyone know they are worthy of love?

Janine appears like she will throw one bouquet to one person, then surprises everyone when the flowers are untied and everybody catches a flower. 

Do they have a party afterwards? What music?

A dancing party with the music of Cleo Laine, Harry Belafonte, Ofra Haza and The Parvarim. 

What is their honeymoon like? Is it a stay at home one? Do they go somewhere exciting? How long is their trip?

A three week vacation to San Diego, California.

How many kids do they have? What are their names?

Three kids: Noemi, Tobin and Batya.

NICKNAME(S): Baby Smurf, Sugar Plum.

FACECLAIM: Violet Ramis (child), Jenny Slate (adult).

BIRTH: August 25th 1984.

ZODIAC SIGN: Virgo.

SEXUALITY: Bissexual.

GENDER: Female.

ORIGIN: Forest Hills, Queens, New York City.

NATIONALITY: US American.

CHARACTERISTICS:

+ Curious, inquisitive, creative, extroverted, with a fascination for gallows humor;

+ Loves colorful clothes, cartoons and comic books;

+ Has a strong temper and rarely disguises when she has either contempt or desire to kill someone she perceives as an enemy;

WEAPON OF CHOICE:

+ P.K.E Meter

+ Proton Pack

+ Ghost Trap

OTHER PERSONAL INFO: 

+ While she inherited the academic talent of her father, she has the more outgoing and bold approach to social interactions of her mother;

+ Considers the other Ghostbusters her uncles, with Ray and Winston being her favorites;

+ Is a huge fan of the Smurfs and Asterix comics and cartoons and a cosplayer;

+ Before deciding to pursue a career in STEM and Parapsychology, for a while she considered taking religious studies to become a rabbi. While she didn't went through with that, she still became and expert in Jewish Mythology and Folklore;

+ Besides being a Ghostbuster, Noemi also teaches about the paranormal at Columbia University.

NICKNAME(S): Bean Bunny.

FACECLAIM: Anton Yelchin (child and adult).

BIRTH: June 23th 1989.

ZODIAC SIGN: Cancer.

SEXUALITY: Asexual.

GENDER: Male.

ORIGIN: Forest Hills, Queens, New York City.

NATIONALITY: US American.

CHARACTERISTICS:

+ Calm, caring, empathetic, studious, who enjoys safety and tranquility;

+ Loves cooking, gardening and drawing;

+ Is anxious and gets stuck in a place when frightened;

WEAPON OF CHOICE:

+ P.K.E Meter

+ Ghost Trap

OTHER PERSONAL INFO:

+ Has the more quiet temperament of his father, and the belief in intuition from his mother, wich is formative of his view of science mainly as an instrument of nurturing;

+ Collects mold, spores and fungus, and also enjoys botanics, specially harvesting the mushrooms, fruits and vegetables to use in dishes he cooks for his friends and family;

+ Loves the Pogo comic strips, Fraggle Rock and the Dave the Gnome cartoon;

+ Studies to become a Landscape Architect, Environmental Engineer and Manager;

+ When reluctantly involved in Ghostbusting by his older sister, he only uses the P.K.E Meter and the Ghost Trap, seeing these instruments as something to try to communicate with the ghosts and help them get shelter and defend humans from harm, but he doesn’t handle the Proton Pack because is heavy and because he sees it as a intimidating gun.

NICKNAME(S): Ladybug.

FACECLAIM: Flora Guiet (child), Alexandra Socha (adult).

BIRTH: September 29th 1991.

ZODIAC SIGN: Libra.

SEXUALITY: Biromantic and demisexual.

GENDER: Female.

ORIGIN: Forest Hills, Queens, New York City.

NATIONALITY: US American.

CHARACTERISTICS: 

+ Likes to keep things well organized to facilitate the work and everyday life of other people;

+ Physically agile;

+ In a conversation, can see connections between topics that the other person listening her would never imagine being related;

WEAPON OF CHOICE:

+Walkie-talkie

+Proton Pack

+Ghost Trap

+ Ecto Goggles

OTHER PERSONAL INFO: 

+ Inherited her mother’s taste for racquetball, and also plays tennis;

+ Loves RPG, be they tabletop or video games, eventually getting a Masters Degree in Game Theory and Game Design;

+ Is fascinated with prehistoric animals, studying History, Biology, Zoology, Archeology and Paleontology, the area where she intends to become a Doctor;

+ Also enjoys photography;

+ Is a mix between a Explorer Historian, whose greatest pleasure is delving into the new world that they are exploring in search of knowledge as the greatest reward, and a Socializer Strategist, happy to collaborate in order to achieve bigger and better things than she could on her own, while having no problems assuming leadership if it means keeping the group safe and sound when the situation becomes especially dangerous.

Where do they live?

In an old two storey boarding house in Forest Hills, Queens, chosen because it looked similar to a drawing that Janine made in her childhood of her dream house, which should be old and covered with vines like the house that served as Madeline's boarding school. 

[screenshots123]

📅 Aug 2023 📰 New mRNA-based malaria vaccine shows promise in preclinical trials 🗞 News-Medical.net

The focus of the collaborative research investigating a novel target for malaria was originally on peptide-based vaccines. However, in 2018, the team shifted their approach and started investigating RNA-based vaccines – a decision that, so far, seems to have paid off with the recent success of RNA technology in vaccine development.

"While our successful peptide-based vaccines targeting malaria only contain small protein fragments of a malaria protein, mRNA vaccines encode an entire malaria protein," says the University of Melbourne's Dr Lauren Holz, Research Officer at the Doherty Institute and co-author of the paper.

To pack an extra protective punch, the mRNA vaccine has been combined with an adjuvant – originally developed at the Malaghan and Ferrier Institutes for cancer immunotherapies – which targets and stimulates liver-specific immune cells. This additional ingredient helps localise the RNA vaccine response to the liver, a key site in preventing the parasite from developing and maturing in the body.

"When the parasite first enters the bloodstream, it travels to the liver where it develops and matures before going on to infect blood cells, which is when disease symptoms occur," says Dr Mitch Ganley, Postdoctoral Research Fellow at the Ferrier Research Institute, and co-author of the study.

"Unlike the COVID-19 vaccine that works by neutralizing antibodies, our unique approach relies on T-cells which play a critical role in immunity. Specifically, a type of T-cell called a tissue-resident memory T-cell, that halts malaria infection in the liver to completely stop the spread of infection."

Dr Holz says the key advantage of this vaccine is that it isn't affected by previous exposure to malaria.

"A lot of malaria vaccines undergoing trials have worked really well in animal models or when they're given to people who haven't had malaria before, but they don't work well when given to people living in malaria-endemic regions. In contrast, our vaccine is still capable of generating protective liver-specific immune cells and providing protection even when the animal models have been pre-exposed to the disease," says Dr Holz.

[health-views-updates]

Global Cell Signaling Market Size, Share, Segmentations and Forecast 2032 by Industry Key Players, Solutions and Deployment Types

The global cell signaling market is expected to experience significant growth over the coming decade, with market size forecast to expand from USD 5.1 billion in 2023 to USD 9.4 billion by 2032. This growth represents a compound annual growth rate (CAGR) of 7.1% from 2024 to 2032, driven by advancements in biotechnology, pharmaceuticals, and the growing demand for targeted therapies in cancer and chronic diseases.

Cell signaling refers to the complex system of communication that governs basic cellular activities and coordinates cell actions. It is a critical process in maintaining homeostasis, as well as in the development of diseases. This intricate communication system is central to understanding a wide range of physiological processes and pathologies, including cancer, immunology, and neurobiology.

Key Market Drivers

Rising Prevalence of Chronic Diseases: One of the primary drivers of growth in the cell signaling market is the increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, diabetes, and neurodegenerative disorders. These diseases often result from disrupted or abnormal cell signaling pathways. Consequently, there is a growing demand for research into targeted therapies that can precisely modulate these signaling pathways to treat such conditions. The development of drugs that act on specific signaling molecules has become a major area of focus in the pharmaceutical industry, driving market expansion.

Technological Advancements in Molecular Biology: Rapid advancements in molecular biology and biotechnology have led to breakthroughs in understanding cell signaling pathways. Technologies such as CRISPR gene editing, high-throughput screening, and next-generation sequencing are enabling researchers to study signaling networks at unprecedented levels of detail. These innovations have spurred the development of new diagnostic tools and therapeutic approaches aimed at modulating cell signaling in disease states.

Increasing Focus on Personalized Medicine: The shift toward personalized medicine, where treatments are tailored to an individual’s genetic makeup and specific cellular processes, is another major factor propelling the growth of the cell signaling market. By gaining a better understanding of an individual’s cell signaling pathways, healthcare providers can develop more effective and less toxic treatment plans, particularly for complex conditions like cancer. Personalized medicine is revolutionizing healthcare, and cell signaling research is at the heart of these innovations.

Investment in Cancer Research: Cell signaling research plays a critical role in oncology, as cancer is often driven by mutations in signaling pathways that control cell growth, division, and death. The market is benefiting from substantial investments in cancer research, with a focus on discovering and developing novel therapies that target specific signaling molecules or pathways involved in tumor progression. The introduction of targeted therapies, such as tyrosine kinase inhibitors and immunotherapies, has already transformed cancer treatment and continues to drive growth in this sector.

Get Free Sample Report: https://www.snsinsider.com/sample-request/4501 

Challenges and Opportunities

While the cell signaling market shows great potential, there are challenges that may affect growth. The complexity of cell signaling pathways, the high cost of research, and the time required to develop effective therapies can be significant barriers to market entry. Additionally, regulatory hurdles for new therapies targeting cell signaling molecules can slow down the approval process.

However, these challenges present opportunities for further innovation. Continued research into unexplored signaling pathways and the application of cutting-edge technologies like artificial intelligence (AI) in drug discovery are expected to drive new developments. AI and machine learning are already being used to predict signaling pathway interactions and optimize drug candidates, streamlining the drug development process and reducing costs.

Regional Insights

North America is the largest market for cell signaling, owing to the region’s robust biopharmaceutical industry, high investment in healthcare research, and the presence of key players in the field. The U.S. leads in funding for cancer research and targeted therapies, driving significant demand for cell signaling technologies. Europe follows closely, with a strong focus on advancing research in molecular biology and biotechnology.

The Asia-Pacific region is expected to see the fastest growth during the forecast period, supported by increasing government investments in life sciences, expanding pharmaceutical manufacturing, and growing healthcare infrastructure. China, India, and Japan are becoming prominent markets for cell signaling research due to rising healthcare needs and a growing focus on innovative treatments.

Future Outlook

The cell signaling market is poised for sustained growth as demand for precision medicine and advanced therapies continues to rise. With a projected CAGR of 7.1% from 2024 to 2032, the market is set to reach USD 9.4 billion by 2032. As the understanding of cellular communication deepens and new technologies emerge, the market is expected to play a pivotal role in the development of next-generation treatments for a range of diseases, including cancer, autoimmune disorders, and neurological conditions.

In conclusion, the global cell signaling market is on a steady upward trajectory, driven by advancements in biotechnology, growing investment in cancer research, and the increasing focus on personalized medicine. From USD 5.1 billion in 2023, the market is expected to grow to USD 9.4 billion by 2032, reshaping the landscape of drug discovery and disease treatment.

Other Trending Reports

Defibrillator Market

Healthcare Waste Management Market

PET Scanners Market

Antidepressants Market

[crimsonpublisherscancerstudy]

Unstipulated and InexactIndeterminate Dendritic Cell Tumour_Crimson Publishers

Opinion

Indeterminate dendritic cell tumour emerges as an extremely exceptional tumefaction composed of proliferation of dendritic cells or cells of histiocytic lineage. Additionally designated as indeterminate cell histiocytosis, indeterminate cell tumour or indeterminate dendritic cell tumour, true cutaneous dendritic cell tumour may depict solitary or multifocal lesions. Generally, tumefaction is confined to diverse cutaneous surfaces wherein deep seated visceral or regional lymph node involvement is exceptional. Tumour forming indeterminate cells simulate Langerhans cells vis-à-vis morphological and antigenic features. However, indeterminate cells appear devoid of Birbeck granules and lack immune reactivity to langerin (CD207). Median age of disease emergence is 45 years although no age of disease occurrence is exempt. An almost equivalent gender predilection is encountered. Indeterminate dendritic cell tumour predominantly(~88%) implicates diverse cutaneous surfaces. Infrequently, regional lymph nodes (9%) or spleen (2.3%) may be involved [1,2]. Of obscure a etiology, neoplasm expounds varied concurrence between indeterminate cells and Langerhans cells as ~indeterminate cells manifest as Langerhans cells devoid of Birbeck granules ~indeterminate cells represent as immature Langerhans cells. A subset of neoplasms express dendritic cell marker ZBTB46, thereby indicating the emergence of neoplasms directly from bone marrow progenitors, in contrast to embryonic precursors which undergo localized cutaneous regeneration [1,2].

Read more about this article:

For more articles in Novel Approaches in Cancer Study

[colinwilson11]

Merkel Cell Carcinoma Market To Grow At Highest Pace Owing To Rising Incidence Of Merkel Cell Carcinoma

Merkel cell carcinoma (MCC) is a rare form of skin cancer that forms in the skin cells known as Merkel cells or touch receptors. It often appears as a solitary red, purple, or skin-colored nodule on sun-exposed areas such as the head and neck regions. MCC grows and spreads rapidly causing swelling of nearby lymph nodes. Merkel cell carcinoma treatment includes radiation therapy, chemotherapy, and surgery. Depending on the stage of the cancer, treatment options may involve a combination of these therapies.

The Merkel Cell Carcinoma Market  is estimated to be valued at US$ 2.51 Bn in 2024 and is expected to exhibit a CAGR of 4.1% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the Merkel Cell Carcinoma Market are Merck, Incyte Corporation, Kartos Therapeutics, Inc., Bristol-Myers Squibb, and Amgen Inc. Merck and Incyte Corporation are leading pharmaceutical companies offering immunotherapies for Merkel cell carcinoma treatment.

Rising incidence of Merkel cell carcinoma worldwide is a key factor driving the market growth. According to studies, MCC incidence rates have tripled over the past 20 years. Increasing exposure to ultraviolet radiation from sun exposure is contributing to the rising caseload of MCC.

Ongoing research and development activities for developing effective treatment options is fueling market growth. Pharmaceutical companies are engaged in developing monoclonal antibody therapies, immune checkpoint inhibitors, and combination therapies to improve treatment outcomes in Merkel cell carcinoma.

Market Trends

Growing preference for targeted therapy - Introduction of immune checkpoint inhibitors and targeted monoclonal antibody therapies is revolutionizing Merkel cell carcinoma treatment. Drugs like avelumab and pembrolizumab offer more efficacious treatment with fewer side effects compared to chemotherapy.

Rising focus on combination therapies - Combination of chemotherapy with immunotherapy is emerging as a promising treatment approach. Ongoing clinical trials are evaluating efficacy of combining chemotherapies like cisplatin with immune checkpoint inhibitors. Such combination regimens may achieve high response rates.

Market Opportunities

Development of novel drug candidates - Several biotech companies are working on developing novel drug candidates like anti-PD-L1 monoclonal antibodies, vaccines, and oncolytic virus therapies to treat Merkel cell carcinoma. Success of such candidates can reap high returns.

Increasing screening and early diagnosis - Initiatives to raise awareness about MCC and incorporate screening of high-risk groups can help detect MCC at early stages. This provides scope for intervening with curative therapies.

Impact Of COVID-19 On Merkel Cell Carcinoma Market Growth

The COVID-19 pandemic posed significant challenges for the Merkel cell carcinoma market. During the initial phases of the pandemic, patients avoided or delayed medical care due to fears of virus exposure or lockdowns, resulting in delayed diagnosis and treatment of Merkel cell carcinoma. This negatively impacted market growth in the short term. However, as the healthcare systems adapted to the pandemic by implementing strict safety protocols, the number of patients seeking treatment gradually increased. Though the market experienced a temporary dip, the long term impact is expected to be marginal. As the focus shifts to post-COVID recovery, efforts must be made to promote early detection and ensure uninterrupted access to care. Teleoncology can help maintain patient engagement and support. Vaccination drives must continue to alleviate pressure on hospitals and enable prioritization of cancer treatment. With prudent strategies, the market is well-positioned to get back on its pre-pandemic growth trajectory.

Geographical Regions With High Merkel Cell Carcinoma Market Valve Concentration

The United States represents the largest geographical market for Merkel cell carcinoma treatment in terms of value. This is primarily due to the high prevalence of the disease and well-developed healthcare infrastructure in the country. Within the US, states like Florida, California and Arizona have emerged as major hotspots with higher caseloads. These southern regions experience warmer and sunnier weather for most part of the year. Extensive sun exposure increases risk and has contributed to US retaining its top position. Europe is the second largest regional market led by markets like Germany, United Kingdom and France. However, the Asia Pacific region is witnessing fastest market growth driven by improving access to healthcare in India and China. Rising awareness among physicians and public regarding early detection is further propelling the APAC market.

Get more insights on this topic: https://www.ukwebwire.com/merkel-cell-carcinoma-market-poised-for-growth-due-to-advancements-in-targeted-cancer-therapies/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

 What Are The Key Data Covered In This Merkel Cell Carcinoma Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Merkel Cell Carcinoma Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Merkel Cell Carcinoma Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Merkel Cell Carcinoma Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Merkel Cell Carcinoma Market vendors

FAQ’s

Q.1 What are the main factors influencing the Merkel Cell Carcinoma Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Merkel Cell Carcinoma Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Merkel Cell Carcinoma Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[valianttastemakerflower]

Medical Oncology

Medical oncology is a specialized branch of medicine that focuses on the diagnosis, treatment, and management of cancer using non-surgical methods such as chemotherapy, immunotherapy, hormone therapy, and targeted therapies. Medical Oncology it plays a crucial role in the multidisciplinary approach to cancer care, often collaborating with surgical oncologists, radiation oncologists, pathologists, and other specialists to provide comprehensive care for cancer patients.

Overview of Medical Oncology

Medical oncology involves the study and treatment of cancer at the molecular, cellular, and systemic levels. Oncologists use drugs and other therapies to target cancer cells while trying to minimize damage to healthy cells. The field of medical oncology has evolved significantly over the past few decades, with advancements in research leading to better patient outcomes, more personalized treatment plans, and the development of novel therapies.

At the heart of medical oncology is the understanding that every patient’s cancer is unique. Factors such as the type of cancer, its stage, the genetic mutations driving the disease, and the patient’s overall health are all considered when creating a treatment plan. This personalized approach helps maximize the effectiveness of treatment while minimizing side effects.

Role of the Medical Oncologist

A medical oncologist is a doctor who specializes in treating cancer with medications. Their responsibilities include:

Diagnosis and Staging: After confirming the presence of cancer through biopsies, imaging tests, and laboratory results, medical oncologists determine the cancer’s stage. Staging helps assess how far the cancer has spread and is critical in determining the treatment approach.

Treatment Planning: Medical oncologists work closely with other specialists to create a personalized treatment plan. This plan may include chemotherapy, targeted therapy, immunotherapy, or hormone therapy, depending on the type of cancer and its progression.

Administration of Chemotherapy and Other Medications: Medical oncologists administer chemotherapy, which uses drugs to kill cancer cells or stop them from growing. They also oversee the delivery of immunotherapy (which boosts the immune system to fight cancer) and targeted therapy (which focuses on specific genetic mutations or proteins in cancer cells).

Management of Side Effects: Cancer treatments can cause various side effects, such as nausea, fatigue, pain, or infections. Medical oncologists manage these side effects and work to improve the patient's quality of life during treatment.

Surveillance and Follow-Up Care: After treatment, medical oncologists continue to monitor the patient for recurrence of cancer and provide long-term follow-up care. They also focus on survivorship issues, including managing late effects of treatment and overall health maintenance.

Types of Cancer Treated by Medical Oncologists

Medical oncologists treat various types of cancer, including but not limited to:

Breast cancer: One of the most common cancers worldwide, often treated with a combination of chemotherapy, hormone therapy, and targeted therapy.

Lung cancer: Medical oncology plays a critical role in treating both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) with chemotherapy, immunotherapy, and targeted therapies.

Colorectal cancer: This includes cancers of the colon and rectum, which are frequently treated with chemotherapy, sometimes in combination with surgery.

Prostate cancer: Hormone therapy is a key treatment option for prostate cancer, often combined with chemotherapy or immunotherapy in advanced cases.

Lymphomas and Leukemias: These are cancers of the blood and lymphatic system, often treated with chemotherapy, immunotherapy, and sometimes bone marrow transplants.

Key Treatments in Medical Oncology

1. Chemotherapy

Chemotherapy is one of the most well-known treatments in medical oncology. It involves the use of powerful drugs to kill cancer cells or prevent them from dividing and spreading. Chemotherapy is often used in combination with other therapies, such as surgery or radiation therapy, to ensure comprehensive cancer treatment. The drugs can be administered intravenously or orally and are typically given in cycles to allow the body time to recover between treatments.

2. Immunotherapy

Immunotherapy is a rapidly growing area of cancer treatment. It works by boosting the body’s immune system to fight cancer cells more effectively. Types of immunotherapy include checkpoint inhibitors, CAR T-cell therapy, and cytokines. Unlike chemotherapy, which attacks cancer cells directly, immunotherapy enhances the body's immune response to cancer.

3. Targeted Therapy

Targeted therapy is a more precise treatment that focuses on specific genes or proteins that are involved in the growth and survival of cancer cells. These therapies are designed to attack only cancer cells while sparing normal cells, thus reducing side effects. Commonly used targeted therapies include monoclonal antibodies and small-molecule inhibitors.

4. Hormone Therapy

Hormone therapy is used to treat cancers that rely on hormones to grow, such as breast and prostate cancer. By blocking the body’s ability to produce certain hormones or interfering with the effects of hormones, this treatment can slow or stop the growth of cancer cells.

Advances in Medical Oncology

Medical oncology is a dynamic and constantly evolving field. With ongoing research, new treatments and therapies are continually being developed. Some of the recent advances in medical oncology include:

Precision Medicine: Advances in genomic profiling have enabled the development of personalized treatments based on the genetic makeup of a patient’s tumor. Precision medicine allows oncologists to target specific mutations driving the cancer, leading to more effective treatment and fewer side effects.

Combination Therapies: Research has shown that combining different types of therapies—such as chemotherapy with immunotherapy or targeted therapy—can lead to better outcomes for patients. These combination therapies are becoming increasingly common in the treatment of various cancers.

Liquid Biopsies: Liquid biopsy is a new diagnostic tool that allows oncologists to detect cancer through a simple blood test. It offers a less invasive alternative to traditional tissue biopsies and can provide real-time information on how a patient’s cancer is responding to treatment.

CAR T-Cell Therapy: This innovative form of immunotherapy involves modifying a patient’s own T-cells to recognize and attack cancer cells. CAR T-cell therapy has shown remarkable success in treating certain types of blood cancers and is being explored for use in solid tumors as well.

The Role of Clinical Trials in Medical Oncology

Clinical trials are essential to the advancement of medical oncology. They allow oncologists to test new treatments and therapies, often offering patients access to cutting-edge treatments that are not yet widely available. Participation in clinical trials is voluntary, and patients are carefully monitored throughout the trial to ensure their safety.

For many patients, clinical trials represent hope, especially when standard treatments have failed. Medical oncologists play a vital role in identifying suitable trials for their patients and guiding them through the process.

Medaura’s Contribution to Medical Oncology

Medaura, a reputed healthcare institution, is at the forefront of medical oncology services. It provides a multidisciplinary approach to cancer treatment, incorporating advanced technologies and cutting-edge therapies to offer personalized care to each patient. Medaura’s team of medical oncologists works collaboratively with specialists in surgery, radiation, and palliative care to ensure that patients receive comprehensive and holistic treatment.

Medaura is equipped with state-of-the-art diagnostic facilities that allow for accurate staging and molecular profiling of cancers, which forms the basis for personalized treatment strategies. The center is also actively involved in clinical trials, giving patients access to novel treatments and the latest developments in cancer research.

In addition to treatment, Medaura is deeply committed to cancer prevention and education. The institution runs awareness programs, cancer screenings, and survivorship support groups, providing holistic support to patients and their families throughout their cancer journey.

Conclusion

Medical oncology is a critical component of modern cancer treatment, combining science, innovation, and compassion to fight one of the most challenging diseases of our time. Advances in chemotherapy, immunotherapy, and targeted therapies have significantly improved survival rates and quality of life for cancer patients. Institutions like Medaura are leading the way in providing high-quality oncology care, making a profound impact on the lives of patients battling cancer.

[jcmarchi]

Engineers develop a vibrating, ingestible capsule that might help treat obesity

New Post has been published on https://thedigitalinsider.com/engineers-develop-a-vibrating-ingestible-capsule-that-might-help-treat-obesity/

Engineers develop a vibrating, ingestible capsule that might help treat obesity

When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it’s time to stop eating. A stomach full of liquid can also send these messages, which is why dieters are often advised to drink a glass of water before eating.

MIT engineers have now come up with a new way to take advantage of that phenomenon, using an ingestible capsule that vibrates within the stomach. These vibrations activate the same stretch receptors that sense when the stomach is distended, creating an illusory sense of fullness.

In animals who were given this pill 20 minutes before eating, the researchers found that this treatment not only stimulated the release of hormones that signal satiety, but also reduced the animals’ food intake by about 40 percent. Scientists have much more to learn about the mechanisms that influence human body weight, but if further research suggests this technology could be safely used in humans, such a pill might offer a minimally invasive way to treat obesity, the researchers say.

“For somebody who wants to lose weight or control their appetite, it could be taken before each meal,” says Shriya Srinivasan PhD ’20, a former MIT graduate student and postdoc who is now an assistant professor of bioengineering at Harvard University. “This could be really interesting in that it would provide an option that could minimize the side effects that we see with the other pharmacological treatments out there.”

Srinivasan is the lead author of the new study, which appears today in Science Advances. Giovanni Traverso, an associate professor of mechanical engineering at MIT and a gastroenterologist at Brigham and Women’s Hospital, is the senior author of the paper.

A sense of fullness

When the stomach becomes distended, specialized cells called mechanoreceptors sense that stretching and send signals to the brain via the vagus nerve. As a result, the brain stimulates production of insulin, as well as hormones such as C-peptide, Pyy, and GLP-1. All of these hormones work together to help people digest their food, feel full, and stop eating. At the same time, levels of ghrelin, a hunger-promoting hormone, go down.

While a graduate student at MIT, Srinivasan became interested in the idea of controlling this process by artificially stretching the mechanoreceptors that line the stomach, through vibration. Previous research had shown that vibration applied to a muscle can induce a sense that the muscle has stretched farther than it actually has.

“I wondered if we could activate stretch receptors in the stomach by vibrating them and having them perceive that the entire stomach has been expanded, to create an illusory sense of distension that could modulate hormones and eating patterns,” Srinivasan says.

As a postdoc in MIT’s Koch Institute for Integrative Cancer Research, Srinivasan worked closely with Traverso’s lab, which has developed many novel approaches to oral delivery of drugs and electronic devices. For this study, Srinivasan, Traverso, and a team of researchers designed a capsule about the size of a multivitamin, that includes a vibrating element. When the pill, which is powered by a small silver oxide battery, reaches the stomach, acidic gastric fluids dissolve a gelatinous membrane that covers the capsule, completing the electronic circuit that activates the vibrating motor.

In a study in animals, the researchers showed that once the pill begins vibrating, it activates mechanoreceptors, which send signals to the brain through stimulation of the vagus nerve. The researchers tracked hormone levels during the periods when the device was vibrating and found that they mirrored the hormone release patterns seen following a meal, even when the animals had fasted.

The researchers then tested the effects of this stimulation on the animals’ appetite. They found that when the pill was activated for about 20 minutes, before the animals were offered food, they consumed 40 percent less, on average, than they did when the pill was not activated. The animals also gained weight more slowly during periods when they were treated with the vibrating pill.

“The behavioral change is profound, and that’s using the endogenous system rather than any exogenous therapeutic. We have the potential to overcome some of the challenges and costs associated with delivery of biologic drugs by modulating the enteric nervous system,” Traverso says.

The current version of the pill is designed to vibrate for about 30 minutes after arriving in the stomach, but the researchers plan to explore the possibility of adapting it to remain in the stomach for longer periods of time, where it could be turned on and off wirelessly as needed. In the animal studies, the pills passed through the digestive tract within four or five days.

The study also found that the animals did not show any signs of obstruction, perforation, or other negative impacts while the pill was in their digestive tract.

An alternative approach

This type of pill could offer an alternative to the current approaches to treating obesity, the researchers say. Nonmedical interventions such as diet exercise don’t always work, and many of the existing medical interventions are fairly invasive. These include gastric bypass surgery, as well as gastric balloons, which are no longer used widely in the United States due to safety concerns.

Drugs such as GLP-1 agonists can also aid weight loss, but most of them have to be injected, and they are unaffordable for many people. According to Srinivasan, the MIT capsules could be manufactured at a cost that would make them available to people who don’t have access to more expensive treatment options.

“For a lot of populations, some of the more effective therapies for obesity are very costly. At scale, our device could be manufactured at a pretty cost-effective price point,” she says. “I’d love to see how this would transform care and therapy for people in global health settings who may not have access to some of the more sophisticated or expensive options that are available today.”

The researchers now plan to explore ways to scale up the manufacturing of the capsules, which could enable clinical trials in humans. Such studies would be important to learn more about the devices’ safety, as well as determine the best time to swallow the capsule before to a meal and how often it would need to be administered.

Other authors of the paper include Amro Alshareef, Alexandria Hwang, Ceara Byrne, Johannes Kuosmann, Keiko Ishida, Joshua Jenkins, Sabrina Liu, Wiam Abdalla Mohammed Madani, Alison Hayward, and Niora Fabian.

The research was funded by the National Institutes of Health, Novo Nordisk, the Department of Mechanical Engineering at MIT, a Schmidt Science Fellowship, and the National Science Foundation.

[priteshwemarketresearch]

Carfilzomib Market Overview and Regional Outlook Study 2024 – 2034

Carfilzomib Market Defination:

TheCarfilzomib Market refers to the economic and clinical landscape surrounding the pharmaceutical drug carfilzomib. Carfilzomib is a proteasome inhibitor used primarily in the treatment of multiple myeloma, a type of cancer affecting plasma cells in bone marrow. It functions by selectively inhibiting the proteasome, a complex protein-degrading machinery essential for cell function and survival. This inhibition leads to the accumulation of proteins within cancer cells, triggering cell death through apoptosis.

Print This Guide for Future Reference:https://wemarketresearch.com/reports/request-free-sample-pdf/carfilzomib-market/1493

Exploring the Carfilzomib Market: Advancements in Multiple Myeloma Treatment

In the realm of oncology, particularly in the treatment landscape of multiple myeloma, carfilzomib has emerged as a cornerstone therapy, offering new hope and improved outcomes for patients. This blog delves into the dynamic carfilzomib market, examining its impact, current trends, challenges, and future prospects.

Understanding Carfilzomib

Carfilzomib is a proteasome inhibitor approved for the treatment of relapsed or refractory multiple myeloma. It works by selectively and irreversibly binding to the 20S proteasome, disrupting protein degradation in cancer cells and inducing apoptosis. Approved by the FDA in 2012, carfilzomib has since been integrated into treatment protocols, often in combination with other agents like lenalidomide and dexamethasone.

Market Dynamics

Current Landscape: The Carfilzomib Market is driven by its efficacy in treating relapsed or refractory multiple myeloma, particularly in patients who have received prior therapies. Its mechanism of action and clinical benefits have positioned it as a valuable option in the treatment algorithm for multiple myeloma.

Treatment Advancements: Clinical studies have demonstrated that carfilzomib-based regimens prolong progression-free survival and overall survival compared to traditional therapies. Its approval marked a significant advancement in the management of multiple myeloma, offering a targeted approach to combating the disease.

Competitive Environment: Within the proteasome inhibitor class, carfilzomib competes with bortezomib and ixazomib, each offering unique profiles in terms of efficacy, safety, and administration convenience. Ongoing research aims to optimize carfilzomib’s use through novel combinations and sequencing strategies to maximize patient benefit.

Clinical Applications

Approved Indications: Carfilzomib is primarily indicated for use in combination with other agents for the treatment of relapsed or refractory multiple myeloma. Clinical trials are also exploring its potential in newly diagnosed patients and maintenance therapy settings, broadening its scope of application.

Future Directions: Research efforts are focused on expanding carfilzomib’s indications and understanding its synergies with emerging therapies such as immunomodulators, monoclonal antibodies, and cellular therapies like CAR-T cells. These endeavors aim to further improve treatment outcomes and offer personalized therapeutic approaches.

Carfilzomib Market Challenges and Opportunities

Challenges: Economic considerations remain a significant challenge in the adoption of carfilzomib, given its high cost as a biologic therapy. Managing treatment-related adverse events, such as cardiovascular complications and hematologic toxicities, also requires vigilant monitoring and proactive management strategies.

Opportunities: Advances in biomarker identification and personalized medicine offer opportunities to tailor carfilzomib-based therapies to individual patient profiles. Moreover, ongoing research into combination therapies and novel formulations aims to enhance efficacy while minimizing adverse effects, thereby improving patient adherence and outcomes.

Patient Impact and Healthcare Considerations

Patient Experience: For patients diagnosed with relapsed or refractory multiple myeloma, carfilzomib represents a crucial treatment option that can potentially extend survival and improve quality of life. Education and support programs play a vital role in helping patients manage treatment-related challenges and adhere to therapy.

Healthcare System Implications: Integrating carfilzomib into clinical practice requires healthcare providers to navigate complex treatment algorithms and ensure appropriate patient monitoring. Collaboration among multidisciplinary teams, including oncologists, hematologists, and supportive care specialists, is essential for optimizing patient care and outcomes.

Regulatory and Market Access

Regulatory Landscape: Regulatory approvals and reimbursement policies influence the accessibility of cCarfilzomib Market in different regions. Streamlining regulatory processes and demonstrating cost-effectiveness through real-world evidence are crucial for enhancing market access and patient affordability.

Market Expansion: As clinical data continues to evolve and new indications are explored, the carfilzomib market is poised for growth. Market expansion strategies should prioritize evidence-based medicine and stakeholder collaboration to drive adoption and improve patient access.

Conclusion

In conclusion, the carfilzomib market represents a significant advancement in the treatment of multiple myeloma, reflecting the transformative impact of targeted therapies in oncology. Its approval and integration into treatment protocols underscore a shift towards personalized medicine and multidisciplinary care approaches that optimize patient outcomes.

While challenges such as economic considerations and treatment-related adverse events persist, ongoing research and collaborative efforts among stakeholders are paving the way for continued innovation and improvement inCarfilzomib-Based Therapies. By addressing these challenges proactively, healthcare providers and pharmaceutical companies can ensure that carfilzomib realizes its full potential in improving the lives of patients battling multiple myeloma.

Stay informed and engaged with the latest developments in the carfilzomib market to contribute to advancements in oncology and patient-centered care.

[healthcaremarketanalysis]

Cell Analysis Market Expected to Grow to $33.9 Billion by 2028

In 2023, the global cell analysis market was estimated at $20.2 billion, with projections to reach $33.9 billion by 2028, growing at a CAGR of 10.9%. The shift towards cell-based assays and increased funding for cell research are primary growth drivers. The new study provides insights into industry trends, pricing, patents, and key stakeholders, showing how cell-based assays enhance drug discovery efficiency over conventional animal testing methods.

Download PDF Brochure

Cell Analysis Market Dynamics

DRIVER: Growing number of drug discovery activities

Adoption of cell-based screening assays has increased in he drug discovery activities to understand associated complexities. Additionally, advances in cell biology, bioinformatics, molecular biology, genomics, and proteomics have generated large volumes of data, owing to which the use of cell-based assays in the drug development process has gained importance. Similarly, the Human Genome Project has generated a number of targets on which drug screening experiments can be carried out. This rapid expansion in drug targets and drug leads in recent years has accelerated the development of cell-based assays for primary and secondary screening in drug discovery.

RESTRAINT: High cost of instruments and restrictions on reagent use

The introduction of high-throughput screening (HTS) and high-content screening (HCS) technologies in cell analysis has increased their reliability. However, these technologies have also resulted in a significant increase in the cost of instruments. Moreover, the time and cost involved in each HTS process are directly proportional to the target molecule’s complexity; consequently, the higher the complexity, the greater the cost. In biopharmaceutical companies, the overall cost of production of biopharmaceuticals has increased considerably due to the use of these expensive systems.

OPPORTUNITY: Application of novel cell-based assays in cancer research

In the last few decades, the incidence and prevalence of cancer have increased significantly across the globe, and this trend is expected to continue in the coming years. In an effort to reduce cancer incidence and mortality, the demand for novel approaches that offer effective cancer diagnosis and treatment has increased in recent years. In this regard, some recent studies have been published that highlight the importance of cell-based assays in cancer research.

Request Sample Pages

Prominent Players:

Danaher (US), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), General Electric (US), Merck KGaA (US), Agilent Technologies (US), Olympus Corporation (Japan), Miltenyi Biotec (US), Bio-Rad Laboratories (US), BioStatus Limited (UK), Fluidigm Corporation (US), NanoCellect Biomedical (US), Cell Biolabs (US), Creative Bioarray (US), Meiji Techno (US), Promega Corporation (US), PerkinElmer (US), Tecan Trading AG (Switzerland), CELLINK (US), QIAGEN (Germany), Corning Incorporated (US), 10x Genomics (US), and Illumina (US).

Recent Developments of Cell Analysis Industry

· In 2023, Becton, Dickinson and Company (US) launched a Spectral Cell Sorter that is coupled with high-speed cell imaging. this product combines real-time imaging technology with spectral flow cytometry.

· In 2020, Miltenyi Biotec (Germany) launched MACS GMP Tyto Cartridge, a GMP-compliant cell sorter..

· In 2020, Bio-Rad Laboratories, Inc. (US) acquired Celsee, Inc., a provider of instruments and consumables for the isolation, detection, and analysis of single cells. This acquisition expanded the company’s product offerings in the flow cytometry market.

Content Source:

[rnomics]

Genes, Vol. 15, Pages 1161: Simultaneous Visualization of R-Loops/#RNA:DNA Hybrids and Replication Forks in a DNA Combing Assay

R-loops, structures that play a crucial role in various biological processes, are integral to gene expression, the maintenance of genome stability, and the formation of epigenomic signatures. When these R-loops are deregulated, they can contribute to the development of serious health conditions, including #cancer and neurodegenerative diseases. The detection of R-loops is a complex process that involves several approaches. These include S9.6 antibody- or #RNAse H-based immunoprecipitation, non-denaturing bisulfite footprinting, gel electrophoresis, and electron microscopy. Each of these methods offers unique insights into the nature and behavior of R-loops. In our study, we introduce a novel protocol that has been developed based on a single-molecule DNA combing assay. This innovative approach allows for the direct and simultaneous visualization of #RNA:DNA hybrids and replication forks, providing a more comprehensive understanding of these structures. Our findings confirm the transcriptional origin of the hybrids, adding to the body of knowledge about their formation. Furthermore, we demonstrate that these hybrids have an inhibitory effect on the progression of replication forks, highlighting their potential impact on DNA replication and cellular function. https://www.mdpi.com/2073-4425/15/9/1161?utm_source=dlvr.it&utm_medium=tumblr